Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Advisory Panel to Review Eli Lilly’s JAK Inhibitor Baricitinib on May 30
May 18, 2017
- (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
- MHLW Study Group to Issue Report Calling for Guidelines to Promote Efficient Development of Biosimilars
May 18, 2017
- Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May 17, 2017
- Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May 17, 2017
- 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
- Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
- Japan, South Korea Set Up Working Groups to Collaborate on Harmonization
May 16, 2017
- Procedures for Providing Unapproved Drugs to Developing Countries in Emergencies Could Become Finalized in June
May 15, 2017
- Transition Period of “at Least 1 Year” Needed for New Package Insert Format: MHLW
May 11, 2017
- Marketing Strategies for Participating Hospitals to Be Important for Drug Makers to Effectively Use MID-NET: PMDA Official
May 11, 2017
- LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
- Japan, US Ink Memorandum of Cooperation on Health
May 9, 2017
- Health Minister Shiozaki Stresses Importance of US-Japan Alliance in Healthcare
May 9, 2017
- Japan and India to Share Common View on Global Clinical Trials
May 9, 2017
- “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
- Experts Support Revision of Rules to Promote Concurrent Administration of Multiple Vaccines: MHLW Vaccine Panel
May 8, 2017
- MHLW Study Group Drafts “Items to Consider” to Promote Development of Nucleic Acid Drugs
May 2, 2017
- MHLW Poised to Create Standards for Cancer Treatment in the Elderly
May 1, 2017
- 2017 Economic and Fiscal Policy Guidelines Likely to Be Tinged with MOF Color
April 28, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…